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RESEARCH
Triglyceride profiling in adipose tissues 
from obese insulin sensitive, insulin resistant 
and type 2 diabetes mellitus individuals
Haya Al‑Sulaiti1, Ilhame Diboun2, Sameem Banu1, Mohamed Al‑Emadi3, Parvaneh Amani3, Thomas M. Harvey1, 
Alex S. Dömling4, Aishah Latiff1 and Mohamed A. Elrayess1,5* 
Abstract 
Background: Lipid intermediates produced during triacylglycerols (TAGs) synthesis and lipolysis in adipocytes inter‑
fere with the intracellular insulin signaling pathway and development of insulin resistance. This study aims to compare 
TAG species and their fatty acid composition in adipose tissues from insulin sensitive (IS), insulin resistant (IR) and type 
2 diabetes mellitus (T2DM) obese individuals.
Methods: Human subcutaneous and omental adipose tissue biopsies were obtained from 64 clinically characterized 
obese individuals during weight reduction surgery. TAGs were extracted from the adipose tissues using the Bligh and 
Dyer method, then were subjected to non‑aqueous reverse phase ultra‑high performance liquid chromatography 
and full scan mass spectrometry acquisition and data dependent MS/MS on LTQ dual cell linear ion trap. TAGs and 
their fatty acid contents were identified and compared between IS, IR and T2DM individuals and their levels were cor‑
related with metabolic traits of participants and the adipogenic potential of preadipocyte cultures established from 
their adipose tissues.
Results: Data revealed 76 unique TAG species in adipose tissues identified based on their exact mass. Analysis of TAG 
levels revealed a number of TAGs that were significantly altered with disease progression including C46:4, C48:5, C48:4, 
C38:1, C50:3, C40:2, C56:3, C56:4, C56:7 and C58:7. Enrichment analysis revealed C12:0 fatty acid to be associated with 
TAGs least abundant in T2DM whereas C18:3 was found in both depleted and enriched TAGs in T2DM. Significant cor‑
relations of various adipose tissue‑derived TAG species and metabolic traits were observed, including age and body 
mass index, systemic total cholesterol, TAGs, and interleukin‑6 in addition to adipogenic potential of preadipocytes 
derived from the same adipose tissues.
Conclusion: Pilot data suggest that adipose tissues from obese IR and T2DM individuals exhibit TAG‑specific signa‑
tures that may contribute to their increased risk compared to their IS counterparts. Future experiments are warranted 
to investigate the functional relevance of these specific lipidomic profiles.
Keywords: Lipidomics, Adipose tissue, Triaclyglycerols, Insulin sensitivity, Insulin resistance, Type 2 diabetes mellitus
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
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Background
Adipose tissue is the main site for storing and mobiliz-
ing energy in response to metabolic demand. Obesity is 
associated with changes in the structure and function 
of the adipose tissue, leading to progression of insu-
lin resistance and type 2 diabetes mellitus (T2DM) [1]. 
However, a subset of obese individuals, known as the 
insulin sensitive (IS) obese, maintain insulin sensitivity 
and exhibit better adipose tissue functions compared to 
equally obese insulin resistant (IR) counterparts [2]. Obe-
sity triggers hypertrophy of adipocytes within the subcu-
taneous (SC) adipose tissues to enable accumulation of 
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causes further fat accumulation within the omental (OM) 
depot, which is associated with ectopic fat deposition in 
the liver, skeletal muscle and heart tissues [3]. The subse-
quent hyperinsulinemia inhibits hormone sensitive lipase 
and triggers the lipoprotein lipase causing additional glu-
cose intolerance, hyperinsulinemia, hypertriglyceridemia 
and higher risk of insulin resistance in these tissues [4].
Analysis of complex biological systems has become 
possible by the newly emerging metabolomics tech-
niques where metabolites serve as direct indicators of 
biochemical activity of complex phenotypes such as insu-
lin resistance and T2DM [5]. In this context, lipidomics 
studies were utilized to study differences between SC and 
OM depots. These studies have revealed depot-specific 
enrichment of specific TAGs, glycerophospholipids, and 
sphingolipids and differences in the association of lipid 
species with body mass index, inflammation and insulin 
sensitivity [6, 7]. Although TAGs themselves are unlikely 
to be signaling molecules, an increasing body of evidence 
suggests that lipid intermediates produced during TAG 
synthesis or breakdown interfere with the intracellular 
insulin signaling pathway and contribute to the develop-
ment of insulin resistance, including free fatty acids, dia-
cylglycerols and ceramides [8]. Indeed, elevated fatty acid 
efflux from the adipose tissue stimulates TAG synthesis 
in the liver and triggers stress of endoplasmic reticulum 
and stimulation of June kinase pathway in the adipose tis-
sues [9, 10]. This leads to an overload of TAG’s synthetic 
capacity, causing an increase in both diacylglycerols 
(DAGs) and ceramide levels and further development of 
insulin resistance in adipocytes [11].
Despite various studies investigating lipidomic differ-
ences in human serum and adipose tissues in relation to 
insulin sensitivity, no studies have compared differences 
in TAG signatures and their fatty acid composition in 
adipose tissues from IS, IR and T2DM obese individu-
als and their correlations with mediators of metabolic 
disease. Identification of the fatty acids that are enriched 
or depleted in tissues from insulin resistance and T2DM 
individuals could shed light on their functional role in 
disease progression, thus providing potential novel tar-
gets for therapeutic intervention. The aims of this study 
were to profile TAG species and measure their levels in 
two fat depots and to compare their fatty acid composi-
tion between IS, IR and T2DM individuals.
Methods
Materials
Interleukin 6 (IL-6) and leptin ELISAs were from R&D 
systems (Abingdon, UK). Insulin ELISA was from Mer-
codia Diagnostics (Uppsala, Sweden). 4′,6-Diamidino-
2-phenylindole (DAPI), and LipidTOX Green Neutral 
Lipid were from Life Technologies (Warrington, UK). 
Other chemicals and reagents were from Sigma (Munich, 
Germany).
Cohort
Participants’ recruitment criteria were described previ-
ously [12]. Briefly, 64 consented obese individuals under-
going bariatric surgery at AlEmadi hosptial (Doha, Qatar) 
were recruited. Protocols were approved by Institutional 
Review Board of ADLQ (X2017000224). Blood was taken 
prior to operation and 1–5  g of abdominal SC and OM 
adipose tissues biopsies were collected during the surgery 
and stored at − 80  °C until use. Plasma cholesterol, fast-
ing glucose and liver function enzymes were measured by 
COBAS INTEGRA (Roche Diagnostics, Basil). IL-6, leptin 
and insulin were determined using commercially available 
ELISA. Insulin resistance was computed by homeostatic 
model assessment (HOMA-IR) [13] using 30th percentile 
(HOMAIR = 2.4) as a threshold point. Accordingly, sub-
jects were dichotomized into IS (HOMA-IR < 2.4, n = 18, 
3 males and 15 females) and IR (HOMA-IR > 2.4, n = 35, 9 
males and 26 females). Eleven participants were clinically 
diagnosed with T2DM (8 males and 3 females).
Preadipocyte culture and differentiation
Stromal vascular fraction (SVF) cells were obtained by col-
lagenase digestion of adipose tissues as described previously 
[12]. Cell pellets were re-suspended in stromal medium 
containing Dulbecco’s modified Eagle’s Medium-F12 
(DMEM-F12) supplemented with 10% fetal bovine serum 
(FBS) and Penicillin/Streptomycin, then maintained at 
37 °C with 5%  CO2 until confluence. To induce differentia-
tion, early passaged stromal vascular fraction (SVF)-derived 
preadipocytes (passages 1–3) were grown at 2 × 104/cm2 
in stromal medium overnight, then incubated in differen-
tiation medium (DMEM-F12, 3% FBS, 33 μM biotin, 17 μM 
d-pantothenate, 1 μM dexamethasone, 250 μM of methyl-
isobutylxanthine, 0.1  μM human insulin, 5  μM of Peroxi-
some proliferator-activated receptor gamma PPARγ agonist, 
rosiglitazone) for 7 days, followed by 12 days in maintenance 
medium containing the same components as the differen-
tiation medium but omitting methylisobutylxanthine and 
rosiglitazone. Differentiation potential (adipogenic capacity) 
was determined as a percentage of lipidtox positive stained 
cells to total number of stained nuclei (DAPI).
Sample preparation
Human SC and OM adipose tissue specimens from IS, IR 
and T2DM individuals were extracted using the Bligh and 
Dyer Method [14]. Homogenization of tissue was car-
ried out in the gentle MACS Dissociator (Miltenyi Bio-
tech, Germany) with one volume of PBS for every gram 
of tissue. Following tissue homogenization, 1 mL of each 
sample solution was transferred into a separate 15  mL 
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Falcon tube, and 3 mL of 3:1 ratio of Chloroform:MeOH 
were added into each tube. One microliter of PBS was 
added and samples were centrifuged at 3000 RPM for 
20 min at room temperature. The organic layer (bottom 
layer) was carefully transferred into new 15  mL Falcon 
tubes and evaporated to dryness under a stream of high 
purity nitrogen. Samples were then reconstituted with 
1:1:1 mixture of hexane, isopropanol, acetonitrile. Subse-
quently the extracts were analysed using data dependent 
full scan MS and MS/MS acquisition using the Thermo 
LTQ VelosPro dual cell linear ion trap mass spectrometer 
(Thermo Fisher Scientific, San Jose, CA, USA).
Sample analysis
Separation of TAGs was carried out using non-aqueous 
reverse phase UHPLC separation (NARP), on a Dionex Ulti-
mate 3000 UHPLC system, using acetonitrile w/0.1% formic 
acid (eluent A), and isopropanol w/10  mM ammonium 
formate (eluent B) as the mobile phase. The column was a 
Phenomenex UHPLC C30 core shell, 150  mm × 2.1  mm 
and 2.7 µm particle size (Phenomenex Torrance CA, USA). 
Gradient conditions started with 5% B held for 2 min, then 
raised to 50% B at 30 min, held for 10 min and then reduced 
to 5% B at 45 min and held for further 5 min.
Mass spectrometry
MS analyses were conducted using the Thermo LTQ 
VelosPro dual cell linear ion trap mass spectrometer 
(Thermo Fisher Scientific, San Jose, CA, USA), acquir-
ing both full scan MS and subsequent data dependent full 
scan MS/MS product ion spectra with wide band activa-
tion. Target parent ions were automatically selected from 
an inclusion list. The low resolution full scan analysis 
provides molecular parent masses  (M+NH4+). These par-
ent ion full scan MS/MS analysis provided further elu-
cidation of possible structures represented in each lipid 
(fatty acid composition). Relative abundances of each 
identified TAG were estimated from the height values for 
each extracted ion current profile for parent masses of 
each compound  (M+NH4+).
Separation by equivalent carbon number
The above UHPLC conditions (NARP) provide separations 
of TAGs by their equivalent carbon number (ECN). The 
ECN is calculated, from the total number of non-glycerol 
carbons in the TAG minus twice the number of the double 
bonds in the molecule (ECN = CN − 2DB). NARP eluted 
the TAGs from lower to higher ECN with increasing per-
cent B in the eluent. NARP-HPLC is commonly used for 
TAG separation because it works on both the chain and 
absolute height or area counts for each identified TAG. As 
some of the TAG may not show baseline resolution, the 
height counts were chosen to better represent the TAG.
Statistical analysis
All statistical analyses were carried out using R ver-
sion 3.2.1 and SIMCA 13.0.1 software (Umetrics, Swe-
den). Variables with skewed distributions were log 
transformed or taken the square root of as appropriate 
to ensure normality. An initial PCA was conducted to 
identify components that explain large proportion of 
the TAG variance. A repeated measures linear model 
incorporating confounders: gender, age, BMI, PC1 and 
PC2 (derived from earlier principle component analysis, 
PCA) and covariates: tissue and diabetic status (IS, IR, 
T2DM) was used to assess the differences in each TAG 
between the two tissues and amongst the insulin/diabe-
tes groups. The model was based on repeated measures 
statistics since a TAG measurement from an individual 
was taken from two separate tissues: SC and OM. The 
model allows the individual inherent variation to be 
taken out of the total variance. Such enhanced model-
ling of the error structure increases the model’s ability 
to detect significance of covariate effects. Nonetheless, 
we have repeated the analysis using the standard linear 
model and confirmed the superiority of the repeated 
measures linear model counterpart. The linear model 
was sometimes used when fitting the repeated meas-
ures model was not possible due to missing data. False 
discovery rate (FDR) multiple testing correction was 
also performed on the differentially expressed TAG 
species identified between adipose tissues from IS, IR 
and T2DM individuals. Fatty acid enrichment amongst 
diabetes/tissue significant TAGs was assessed using the 
one tailed Wilcoxon sum of the ranks test on the list 
of metabolites that differed significantly between IS, 
IR and T2DM after correcting for covariates including 
gender, age, BMI, PC1 and PC2. The analysis was based 
on assessing the likelihood of randomly observing a 
given fatty acid that often amongst highly ranked TAGs 
along the list of all TAGs ordered by p value as follows: 
For each of the following contrasts: subcutaneous ver-
sus omental, IR versus IS, IR versus T2DM and IS ver-
sus T2DM, TAGs were ranked by their p values and a 
given fatty acid mapped to the ranks of TAGs within 
which it is found. The analysis proceeds by assessing the 
likelihood of obtaining the observed sum of fatty acid 
identified ranks by chance. If the fatty acid is observed 
amongst the significant TAG at the top of the list, the 
sum of the ranks would be too small to be explained by 
chance alone; hence the null hypothesis is rejected in 
favor of enrichment. Enrichment hits failed to remain 
significant after FDR multiple testing correction but 
data was reported because of agreement with literature 
as elaborated in “Discussion” section. A similar test was 
used to assess enrichment in constituent fatty acid satu-
ration levels.
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Results
General characteristics of participants
Sixty-four (44 females and 20 males) obese and mor-
bidly obese (BMI = 43.1 ± 7.5 kg/m2) participants were 
recruited from amongst patients undergoing weight 
reduction surgery. Participants exhibited hyperleptine-
mia and hyperinsulinemia and were dichotomized into 
IS and IR groups based on their HOMA-IR index and 
into T2DM based on their medical records. Compared 
to BMI-matched IS and IR subjects, T2DM individu-
als were older and had higher circulating levels of TAG 
and lower leptin (Table 1). Compared to females, males 
had higher mean arterial blood pressure (MAP) (93.7 
vs 84.7, p > 0.01) and lower HDL (1.1 vs 1.5, p = 0.05) 
and leptin (42.0 vs 67.3, p > 0.01) (Additional file  1: 
Table  S1). IS males had lower HOMA-IR than their 
age and BMI-match IS females, whereas IR males had 
higher HOMA-IR than their age, but not BMI, matched 
females (Additional file  1: Table  S1). Compared to 
obese subjects (n = 26), the morbidly obese participants 
(n = 46) had significantly higher BMI, SBP, IL-6, FPG 
and HOMA-IR (Additional file 1: Table S2).
Differences in TAG content between omental 
and subcutaneous adipose tissues
Using a non-targeted approach, a comprehensive par-
ent mass list of 120 identified TAGs was created, of 
which 76 TAG species were identified (Appendix, 
Table  6) based on their molecular weights and peak 
heights. A linear model was used to assess depot-spe-
cific TAG associations after correcting for participant 
diabetes group, gender, PC1 and PC2 (refer to “meth-
ods” section). Analysis revealed 7 TAGs that were sig-
nificantly different between SC and OM tissues. C53:5, 
C51:3, C50:4, C59:1, C54:6 and C50:2 were higher in 
OM than SC. C38:1 was higher in the SC compared 
to OM tissues. The full scan MS/MS analysis revealed 
the fatty acid composition for each identified TAG 
(Table 2).
TAGs with varying levels between IS, IR and T2DM
A linear model was used to assess TAG associations 
with participant groups after correcting for possible 
confounders (refer to “Methods” section). A number of 
TAGs were significantly decreased in T2DM compared to 
IS and/or IR including C46:4, C48:5, C48:4, C38:1, C50:3 
and C40:2 whereas a number of TAGs were increased 
in T2DM compared to the other two groups including 
C56:3, C56:4, C56:7 and C58:7. No significant differences 
in TAGs between IS and IR groups was detected. Table 3 
summarizes the list of differentially expressed TAGs with 
their fatty acids compositions. When looking at gender 
versus group (IS, IR and T2DM) interaction, there were 
no FDR significant interaction effects. However, when 
considering BMI versus group interaction, two TAG spe-
cies showed FDR significant interaction effects includ-
ing C40:2 and C53:4. Whereas the former (C40:1) shows 
Table 1 General characteristics of participants
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial blood pressure, LDL low density lipoprotein, HDL high density 
lipoprotein, IL-6 interleukin 6, FPG fasting blood glucose, HOMA-IR homeostatic model assessment of insulin resistance. Data are presented as mean (SD). Differences 
between IS, IR and T2DM were tested by ANOVA. Differences between (IS+IR vs T2DM) were tested by the independent‑sample t test or Mann–Whitney U test. A p 
value significance level of 0.05 was used
Variables IS IR T2DM P value IS+IR P value
(N = 18) (N = 35) (N = 11) ANOVA IS vs IR IS vs T2DM IR vs T2DM (N = 46) IS+IR vs T2DM
Age (years) 32.09 (9.7) 30.26 (9.3) 43.57 (9.4) 0.000 0.739 0.017 0.003 30.9 (9.4) 0.001
BMI (kg  m−2) 41.44 (7.0) 43.31 (6.9) 45.53 (9.6) 0.38 0.583 0.394 0.731 42.7 (6.9) 0.322
SBP (mmHg) 119.0 (13.8) 122.67 (15.7) 132.14 (11.6) 0.13 0.616 0.111 0.268 121.5 (15.1) 0.075
DBP (mmHg) 66.1 (9.8) 69.98 (12.7) 73.33 (7.0) 0.3 0.422 0.369 0.783 68.7 (11.9) 0.35
MAP 83.4 (8.1) 88.08 (12.4) 93.53 (8.9) 0.11 0.288 0.130 0.499 86.6 (11.3) 0.15
Cholesterol (mmol/L) 4.4 (0.9) 4.6 (1.2) 5.22 (0.9) 0.24 0.785 0.215 0.364 4.5 (1.1) 0.122
LDL (mmol/L) 2.73 (0.8) 2.91 (0.9) 3.1 (1.0) 0.55 0.693 0.593 0.855 2.8 (0.8) 0.466
HDL (mmol/L) 1.33 (0.4) 1.46 (0.9) 1.29 (0.3) 0.74 0.793 0.990 0.844 1.4 (0.8) 0.678
Triglyceride (mmol/L) 1.13 (0.6) 1.27 (0.7) 1.91 (1.1) 0.04 0.729 0.031 0.072 1.2 (0.6) 0.015
Leptin (ng/mL) 64.36 (25.5) 60.7 (21.9) 39.16 (31.5) 0.06 0.854 0.055 0.091 62.1 (23.1) 0.021
Adiponetin (ng/mL) 3.24 (2.2) 3.62 (1.9) 3.47 (2.4) 0.88 0.866 0.982 0.992 3.5 (1.9) 0.979
IL‑6 (pg/mL) 3.28 (1.8) 3.72 (1.8) 4.03 (2.2) 0.58 0.683 0.627 0.913 3.6 (1.8) 0.521
FBG (mmol/L) 5.73 (2.5) 12.76 (8.4) 12.84 (6.5) 0.000 0.001 0.072 1.000 10.3 (7.7) 0.439
Insulin (mIU/L) 6.33 (1.9) 12.6 (10.0) 11.92 (6.4) 0.01 0.010 0.241 0.976 10.3 (8.6) 0.633
HOMA‑IR 1.56 (0.6) 4.86 (2.0) 6.6 (3.2) 0.000 0.000 0.000 0.080 3.7 (2.3) 0.005
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more pronounced decrease in T2DM compared to IS in 
low BMI than in high BMI, the latter (C53:4) shows a 
more pronounced increase in low BMI than in high BMI 
(Additional file 1: Table S3).
An orthogonal partial least square discriminate anal-
ysis (OPLS-DA) comparing subjects from IS, IR and 
T2DM revealed two significant class-discriminatory 
components (R2X = 0.18, R2Y = 1, R2Q2 = 0.27, CV-
ANOVA p = 0.0001) (Fig.  1). The score plot in Fig.  1a 
indicates an x-axis differentiating the T2DM group 
from IS and IR; the latter two groups being rather sepa-
rated along the y-axis. The corresponding loading score, 
shown in Fig.  1b, features similar TAG/group associa-
tions to those obtained with the linear model (shown 
in Table 3). Specifically, lower amounts of C38:1, C46:4, 
C48:5 and C48:4 as opposed to higher levels of C58:7, 
C56:4, C56:4 and C56:7 in the T2DM group (also cir-
cled in red, Fig. 1b).
In order to study the possible enrichment/depletion 
of certain fatty acid constituents of TAGs in association 
with insulin sensitivity or diabetes, an enrichment analy-
sis based on the Wilcoxon sum of the ranks test was con-
ducted (refer to “Methods” section). The results of the 
analysis are presented in Table  4 and further illustrated 
on Fig.  2. Overall, C12:0 appears to be associated with 
TAGs least abundant in T2DM in both tissues whereas 
C18:3 is found in both depleted and enriched TAGs in 
T2DM (both sides of the x-axis in Fig. 2). This could be 
Table 2 Differential TAG species identified between subcutaneous and omental adipose tissues
Molecular weight (MW), fatty acid composition, fatty acid identity, fold change in SC tissue compared to OM are also indicated
ID TAG MW Fatty acid composition Fatty acids identities Fold change 
(SC-OM)
P value
TAG47 C53:5 866.7 C17:0, C17:1, C19:4 Heptadecanoic acid, cis‑10‑heptadecanoic acid, C19:4 0.17 0.01
TAG2A C38:1 664.7 C18:1, C16:0, C4:0 Oleic acid, palmitic acid, butyric acid − 0.44 0.02
TAG36 C51:3 842.6 C18:1, C16:1, C17:1 Oleic acid, palmitoleic acid, cis‑10‑heptadecenoic acid 0.32 0.03
TAG31 C50:4 826.7 C18:2, C18:2, C14:0 Linoleic acid, linoleic acid, myristic acid 0.37 0.03
TAG81 C59:1 958.8 C23:0, C18:0, C18:1 Tricosanoic acid, stearic acid, oleic acid 0.16 0.04
TAG53A C54:6 878.7 C18:2, C18:2, C18:2 Linoleic acid, linoleic acid, linoleic acid 0.17 0.04
TAG33 C50:2 830.8 C18:2, C16:0, C16:0 Linoleic acid, palmitic acid, palmitic acid 0.19 0.05
Table 3 Differentially expressed TAG species identified between adipose tissues from IS, IR and T2DM individuals
MW molecular weight, fatty acid composition, fatty acid identity, fold change between specified groups are also indicated
ID TAG MW Fatty acid composition Fatty acids identities Comparison Fold change FDR p value
TAG16A C46:4 770.7 C18:2, C18:2, C10:0 Linoleic acid, linoleic acid, capric acid IS vs T2DM − 0.62 0.005
IR vs T2DM − 0.53 0.01
TAG21 C48:5 796.7 C18:2, C18:3, C12:0 Linoleic acid, linolenic acid, lauric acid IR vs T2DM − 0.39 0.0005
IS vs T2DM − 0.38 0.0013
TAG22 C48:4 798.7 C18:2, C18:2, C12:0 Linoleic acid, linoleic acid, lauric acid IR vs T2DM − 0.96 0.002
TAG2A C38:1 664.7 C18:1, C16:0, C4:0 Oleic acid, palmitic acid, butyric acid IS vs T2DM − 1.00 0.0007
TAG32 C50:3 828.8 C16:1, C16:1, C18:1 Palmitoleic acid, palmitoleic acid, oleic acid IR vs T2DM − 0.78 1.37E–05
IS vs T2DM − 0.76 5.62E–05
TAG61 C56:7 904.8 C20:4, C18:1, C18:2 Arachidonic acid, oleic acid, linoleic acid IS vs T2DM 0.81 0.0006
IR vs T2DM 0.74 0.001
TAG64 C56:4 910.8 C18:1, C18:2, C20:1 Oleic acid, linoleic acid, gadoleic acid IS and IR vs T2DM 0.98 0.004
TAG65 C56:3 912.8 C20:1, C18:1, C18:1 Gadoleic acid, oleic acid, oleic acid IR vs T2DM 0.51 0.002
IS vs T2DM 0.54 0.002
TAG7 C40:2 690.7 C6:0, C16:0, C18:2 Caproic acid, palmitic acid, linoleic acid IS vs T2DM − 1.07 1.26E–05
IR vs T2DM − 0.83 0.0002
TAG74 C58:7 934.8 C18:6, C24:0, C16:1 C18:6, lignoceric acid, palmitoleic acid IS and IR vs T2DM 0.48 0.007
TAG75 C58:4 938.7 C18:3, C24:0, C16:1 Linolenic acid, lignoceric acid, palmitic acid IR vs T2DM 0.69 0.0005
IS vs T2DM 0.73 0.0005
TAG9 C42:2 718.7 C18:2, C12:0, C12:0 Linoleic acid, lauric acid, lauric acid IS vs T2DM − 0.77 0.0008
IR vs T2DM − 0.71 0.001
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justified by a potentially induced flow of C18:3 in certain 
recipient TAGs at the expense of other TAGs with diabe-
tes. Further supporting this are the observed negative cor-
relations between depleted and enriched C18:3 carrying 
TAGs (Fig. 3). Interestingly, many of the C12:0 and C18:3 
containing TAGs, including TAG21, TAG22, TAG75 and 
TAG9, were previously identified as significantly changing 
in level with diabetes by the linear model (Table 3).
Furthermore, C18:3 was also found to have a strong tis-
sue signature featuring frequently amongst highly ranked 
TAGs from statistical analysis of TAG association with 
tissue type (data not shown). However, C18:3 does not 
feature amongst the TAGs found to significantly differ 
between tissues by the linear model (Table 2). This indi-
cates that the collective tissue changes in C18:3 contain-
ing TAGs were rather subtle.
Fig. 1 OPLS‑DA model comparing adipose tissue‑derived TAGs from IS, IR and T2DM individuals. a A score plot showing the class‑discriminatory 
component 1 (x‑axis) versus class‑discriminatory component 2 (y‑axis). b The corresponding loading plot showing similar TAG/diabetes group 
associations to the linear model (circled in red)
Table 4 TAG fatty acid association with  tissue 
and diabetes/insulin sensitivity groups
Analysis conducted using the Wilcoxon sum of the ranks test indicates fatty 
acids that were overrepresented amongst hit TAGs when comparing the groups 
specified in column 1. Comparing IS, IR and T2DM was done in individual 
tissues as well as when pooling data from the two tissues. Similarly, tissues 
were compared per group and when groups were combined (column 2). Only 
significant results are shown at a nominal p value of 0.05
Compared groups Fixed variable Fatty acid p value
IR × T2DM SC C12:0 0.045
SC C18:3 0.048
OM C12:0 0.016
(Full model) SC+OM C12:0 0.025
IS × T2DM OM C12:0 0.03
OM C18:3 0.048
SC × OM (Full model) IS+IR+T2DM C18.3 0.027
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The Wilcoxon sum of the ranks analysis was also used 
to look for enrichment of fatty acid saturation level 
amongst the highly ranked significant TAGs from com-
parison of tissue/diabetes-insulin sensitivity groups but 
no significance was detected.
Correlation of TAG species with mediators of metabolic 
disease
A step-wise regression was performed to identify the 
best TAG predict of various traits including age, BMI, 
systemic TAG, total cholesterol, IL-6 and HOMA-IR, 
SC and OM adipogenic capacity reported previously [12, 
15] and shown in Additional file  2: Figure S1. Table  5 
lists TAG species identified with significant (p = 0.0001) 
association with various metabolic traits and shows their 
importance and fatty acid compositions.
Discussion
TAGs constitute over 99% of lipid species in the adipose 
tissue of healthy individuals, with cholesterol and phos-
pholipids making minor contributions [16]. TAGs are 
located within dynamic functional organelles known as 
lipid droplets that play important roles in intracellular 
vesicle trafficking, cell signaling and lipid homeostasis 
[17]. Although TAGs are not signaling molecules, fatty 
acids produced during their synthesis or breakdown were 
shown to interfere with the intracellular insulin signal-
ing pathway and contribute to the development of insulin 
resistance [10]. Previous studies investigating TAG and 
fatty acid composition between subcutaneous and omen-
tal depots were published [6, 7]. However, this is the 
first study comparing TAGs and their fatty acid species 
in adipose tissues derived from IS, IR and T2DM obese 
individuals. Current technologies enable high-through-
put profiling of the lipidome [18, 19]. In this study, LC/
MS-based lipid profiling was performed to identify adi-
pose signature of obesity-associated insulin sensitivity, 
insulin resistant and T2DM. The emerging data reveal 
differences in TAG species between SC and OM adi-
pose tissues such as C38:1, C53:5, C51:3, C50:4, C59:1, 
C54:6 and C50:2 and among IS, IR and T2DM obese 
individuals including C46:4, C48:5, C48:4, C38:1, C50:3, 
C40:2, C56:3, C56:4, C56:7 and C58:7. The data also show 
Fig. 2 An OPLS‑DA loading plot showing the spread of C12:0 and C18:3 containing TAG along the x‑axis found previously (Fig. 1a) to differentiate 
T2DM from IS+IR subjects. Unlike the C12:0 containing TAGs, the TAGs comprising C18:3 feature on both sides of the x‑axis implying depletion of 
certain recipient TAGs (right side) as oppose to enrichment of others (left side) with diabetes
Fig. 3 A triangular heatmap showing correlations between C18:3 
carrying TAGs
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differences in fatty acid compositions of TAGs associ-
ated with T2DM such as C12:0 and C18:3, suggesting a 
potential functional role of the identified species. Sig-
nificant associations between the identified TAG species 
and traits of metabolic syndrome such as age, BMI, lipids 
(total cholesterol and circulating TAG), the inflammatory 
marker IL-6 and adipogenic capacity of preadipocytes 
derived from the same adipose tissues were identified. 
These associations could shed light on the molecular 
mechanisms contributing to the increased risk of meta-
bolic disease.
Depot specific differences
Our data identified few TAGs that were differently 
expressed between SC and OM tissues. One TAG that 
was higher in SC compared to OM was C38:1, which con-
tains C4:0 (butyric acid). The latter was shown before to 
inhibit lipolysis and increase insulin sensitivity in primary 
rat adipocytes [20], perhaps contributing to the greater 
association of insulin resistance with OM mass com-
pared to SC mass [21]. A previous study in obese men has 
shown increased C50:0, C59:2, C58:2, C60:3, C64:4, C51:0 
and C65:1 fatty acids in OM compared to SC adipose tis-
sues [6]. Changes in lipid composition between the two 
depots were attributed to differences in adipocyte dif-
ferentiation, metabolism of the lipid droplet, and extent 
of beta-oxidation [6]. Differences between the two stud-
ies may reflect ethnic and/or diet differences between our 
Asian and the other study’s Caucasian population. Varia-
tions in fatty acid composition between SC and OM fat 
depots confirm the specific metabolism of each depot, as 
selective lipolytic and lipogenic mechanisms may func-
tion in each tissue depot. Indeed, studies have shown that 
desaturase enzymes, regulating the number of saturated 
fatty acids, exhibit a depot-specific profile [22] in close 
association with insulin resistance [23].
Table 5 List of  TAGs associated with  metabolic traits such as  age, BMI, TC, TG, IL-6, HOMA-IR, SC and  OM adipogenic 
capacity
A step‑wise regression was performed to identify the best TAG predictors of various traits. A p value significance level of 0.001 was used
Metabolic trait R2 Importance TAG MW Fatty acid composition Fatty acids identities
Age 0.4 0.12 C56:1 916.8 C20:0, C18:0, C18:1 Arachidic acid, stearic acid, oleic acid
0.12 C54:8 874.8 C18:3, C18:3, C18:2 Linolenic acid, linolenic acid, linoleic acid
BMI 0.5 0.12 C57:1 930.8 C17:0, C24:0, C16:1 Heptadecanoic acid, lignoceric acid, palmitoleic acid
0.1 C48:1 804.8 C18:0, C16:1, C14:0 Stearic acid, palmitoleic acid, myristic acid
0.09 C54:5 880.8 C18:1, C18:1, C18:3 Oleic acid, oleic acid, linolenic acid
TAG 0.5 0.12 C52:1 860.8 C16:0, C18:1, C18:0 Palmitic acid, oleic acid, stearic acid
0.11 C54:1 888.8 C18:0, C18:0, C18:1 Stearic acid, stearic acid, oleic acid
TC 0.4 0.35 C40:2 690.7 C6:0, C16:0, C18:2 Caproic acid, palmitic acid, linoleic acid
IL‑6 0.6 0.13 C38:1 664.7 C10:0, C12:0, C16:1 Capric acid, lauric acid, palmitoleic acid
0.1 C42:1 720.7 C16:0, C16:1, C10:0 Palmitic acid, palmitoleic acid, capric acid
0.07 C56:1 916.8 C18:0, C18:0, C20:1 Stearic acid, stearic acid, gadoleic
HOMA‑IR 0.5 0.09 C44:2 746.7 C18:2, C14:0, C12:0 Linoleic acid, myristic acid, lauric acid
0.09 C56:7 904.8 C20:4, C18:1, C18:2 Arachidonic acid, oleic acid, linoleic acid
SC adipogenic 0.9 0.16 C58:10 926.8 C18:2, C18:2, C22:6 Linoleic acid, linoleic acid, docosahexaenoic acid
0.16 C56:4 910.8 C18:1, C18:2, C20:1 Oleic acid, linoleic acid, gadoleic acid
0.14 C57:4 924.7 C22:0, C19:4, C16:0 Behenic acid, C19:4, palmitic acid
0.09 C40:1 692.7 C18:1, C16:0, C6:0 Oleic acid, palmitic acid, caproic acid
0.08 C60:1 970.8 C24:0, C24:0, C18:1 Lignoceric acid, lignocerric acid, oleic acid
0.22 C38:1 664.7 C18:1, C16:0, C4:0 Oleic acid, palmitic acid, butyric acid
OM adipogenic 1 0.18 C48:1 804.8 C18:0, C16:1, C14:0 Stearic acid, palmitoleic acid, myristic acid
0.14 C49:1 818.7 C18:1, C17:0, C14:0 Oleic acid, heptadecanoic acid, myristic acid
0.11 C56:1 916.8 C18:0, C18:0, C20:1 Stearic acid, stearic acid, gadoleic
0.09 C54:0 890.8 C18:0, C18:0, C18:0 Stearic acid, stearic acid, stearic acid,
0.06 C38:0 666.7 C10:0, C14:0, C14:0 Capric acid, myristic acid, myristic acid
0.05 C56:2 914.8 C18:1, C18:1, C20:0 Oleic acid, oleic acid, arachidic acid
0.04 C51:1 846.7 C18:1, C15:0, C18:0 Oleic acid, pentadecanoic acid, stearic acid
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IS, IR and T2DM specific differences
Systemic levels of fatty acid increase with obesity and 
T2DM, perhaps as a result of insulin resistance of adi-
pose tissue and subsequent increased lipolysis; although 
in some obese individuals, fatty acid release from adi-
pose tissues is reduced per kg fat in order to normal-
ize plasma non-esterified fatty acid concentrations 
[24]. In our study, significant differences in levels of 
TAG composition were detected between IS, IR and 
T2DM. A number of candidates were either increased 
or decreased with risk of insulin resistance and T2DM, 
despite the predominant view of TAGs as an adverse 
risk factor for diabetes. Using the Wilcoxon sum of 
ranks statistics, fatty acids frequently occurring in 
highly-ranked TAGs along the list of TAGs ordered by p 
value from diabetes association analysis were revealed. 
Two fatty acids were identified: C12:0 and C18:3. The 
strength of this enrichment analysis approach is that, 
unlike the Fishers’ exact test, no arbitrary significance 
cut-off is applied on the list of TAGs. However, a possi-
ble weakness relates to the fact that since the TAGs are 
ordered by p value, no account is given to the direction 
of change and therefore one may not speak of deple-
tion or increase in fatty acid TAG level but rather a 
dynamic in metabolic activity involving the fatty acid 
in association with the phenotype of interest. This was 
observed with C18:3, and a negative correlation was 
noted between C18:3 host TAGs found increased and 
others decreased with diabetes, effectively suggesting a 
metabolic link between the two sets of TAGs. Our find-
ings confirm previous studies that showed significant 
correlations of specific fatty acids with insulin sensitiv-
ity. These include a cross-sectional analysis of adipose 
tissue biopsies from elderly obese men, which identified 
positive correlations between levels of C12:0, C18:2 and 
C18:3 and insulin sensitivity [25]. Our data also con-
firmed the association of C18:3 with metabolic status 
as shown previously in two groups of obese individu-
als who underwent weight loss surgery [26]. Further-
more, subjects in the most insulin-sensitive quintile 
showed a significantly higher percentage of circulating 
C18:2 (pre-cursor of C18:3) than the remaining subjects 
[27], further confirming our data. Functionally, previ-
ous work implicated C18:2 in the modulation of insulin 
signaling in rat skeletal muscle [28]. Therefore, our find-
ings confirm previous results with regard to the asso-
ciation of C12:0 with insulin sensitivity [25], perhaps 
through triggering Glut4 translocation [27]. Our data 
also revealed reduction in C18:3 with T2DM incidents. 
This also confirms previous findings showing a nega-
tive correlation of C18:3 and its precursor with insulin 
resistance and positive association with insulin sensitiv-
ity [27].
Association of TAGs with mediators of metabolic syndrome
Further, our data highlight a panel of TAGs that were 
associated with mediators of metabolic disease in obese 
individuals. Increased age was associated with accu-
mulation of C56:1 that is composed of saturated fatty 
acids C20:0 and C18:0 and mono-unsaturated C18:1, 
whereas age was negatively correlated with C54:8 that 
is composed of unsaturated fatty acids C18:2 and C18:3. 
Although participants had comparable BMI, the small 
increase in BMI was positively correlated with three 
unsaturated TAGs (C57:1, C48:1 and C54:5). Whereas 
circulating TAGs were associated with accumulation 
of C52:1 and C54:1 in the adipose tissue, total choles-
terol was positively correlated with C40:2. The negative 
correlation between IL-6 and C38:1, C42:1 and C56:1 
may suggest an anti-inflammatory effect of fatty acids 
that constitute these TAGs, in particular C10:0 that was 
shown previously to exert an anti-inflammatory proper-
ties [29]. HOMA-IR was also negatively correlated with 
C44:2 and C56:7, both containing C18:2 shown previ-
ously to negatively correlate with insulin resistance [25].
Association of TAGs with adipogenic capacity
Several TAGs were highly correlated with SC or OM 
adipogenic capacity. Previous studies have shown that 
the greater adipogenic capacity of SC and OM preadipo-
cytes taken from IS obese individuals compared to IR and 
T2DM counterparts is partially mediated by lower IL-6 
secretion and oxidative stress [12, 15, 30]. Secretion of 
interleukin IL-6 is significantly decreased after treatment 
with C18:2, C22:6 and C16:0 via inhibition of nuclear fac-
tor kappa B (NF-κB) and subsequent activation of the 
master regulator of adipogenesis, PPARγ [31]. Our data 
revealed positive correlations of C56:4 and C57:4, con-
taining C18:2, C16:0, with SC adipogenic capacity. OM 
adipogenic capacity was associated with C49:1, C38:0 
and C56:2, containing C16:0, C18:1 and C14:0. These 
fatty acids were shown previously to induce adipocyte 
differentiation in rodents [32–36] and potentially play a 
similar role in human preadipocytes.
Study limitations
One main limitation of this study is the relatively low 
number of participants, especially in the T2DM group. 
Additionally, the difference in gender distribution 
between IS and IR groups (predominantly females) and 
T2DM (predominantly males) group may have intro-
duced bias in the study design that may have influenced 
the results. Despite these factors, clear TAG and fatty 
acid signatures were identified after correcting for poten-
tial confounders such as gender and BMI. Another limi-
tation of the current work is its focus on association of 
TAGs with insulin resistance and risk of T2DM without 
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an absolute quantitation of any specific analyte. Incor-
porating isotope-labeled standards would allow absolute 
quantitation and improve the precision of measurements. 
Finally, differences in TAG composition in adipose tis-
sues among the studied groups may have been influenced 
by their diet. Indeed, previous studies have shown that 
the process of fatty acid and TAG deposition in rat adi-
pose tissue depends on the composition of the diet [37]. 
Dietary linoleic acid content was shown to influence the 
distribution of TAG species in rat adipose tissue, particu-
larly di- and trilinoleoyl containing TAG as a result of lin-
oleic acid intake [38]. Other studies have shown that the 
composition of TAG in rat epididymal, subcutaneous and 
perirenal adipose tissues was broadly reflecting dietary 
oils such as isomeric octadecenoic acids from coriander 
oil and high oleic sunflower oil [39]. Taken all these limi-
tations into account, confirmation in different popula-
tions is warranted to validate these findings.
Conclusion
In summary, our data supports the dynamic nature of 
adipose tissue and the complex interaction between adi-
pose tissue physiology and its lipid composition. The 
TAGs and their fatty acid composition within human adi-
pose tissues from obese subjects are markedly different, 
depending on the insulin sensitivity status of the donors. 
Our data suggest that adipose tissues from obese IR and 
T2DM individuals exhibit TAG-specific signatures that 
may contribute to their increased risk compared to their 
insulin-sensitive counterparts or could reflect different 
dietary consumption among the studied groups. Future 
experiments are warranted to investigate the functional 
relevance of these specific lipidomic profiles with refer-
ence to participants’ consumed diet.
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Additional file 1: Table S1. Comparison of participants’ characteristics 
by gender. Table S2. Differences between obese and morbidly obese 
subjects. Table S3. TAGs exhibiting BMI interaction.
Additional file 2: Figure S1. Adipogenic capacity of preadipocytes 
derived from subcutaneous (SC) and omental (OM) adipose tissues from 
insulin sensitive (IS), insulin resistant (IR) and type 2 diabetes mellitus 
(T2DM) patients. Representative images of SC and OM adipocytes form IS 
and IR individuals stained with DAPI in blue (nuclear staining) and lipidtox 
in green (lipid droplet staining) (A). A bar chart showing differences in 
the adipogenic capacity (percentage of differentiated adipocytes to total 
number of nuclei) in SC and OM preadipocytes derived from IS, IR and 
T2DM individuals (B). Significant differences in adipogenic capacity with 
disease progression were detected as reported previously [12, 15].
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Table 6 List of identified TAG, their molecular weights (MW), fatty acid compositions and fatty acids identities
Component name TAG MW Fatty acid composition Fatty acids identities
TAG2 C38:1 664.7 C10:0, C12:0, C16:1 Capric acid, lauric acid, palmitoleic acid
TAG2A C38:1 664.7 C18:1, C16:0, C4:0 Oleic acid, palmitic acid, butyric acid
TAG3 C38:0 666.7 C12:0, C12:0, C14:0 Lauric acid, lauric acid, myristic acid
TAG7 C40:2 690.7 C6:0, C16:0, C18:2 Caproic acid, palmitic acid, linoleic acid
TAG84 C40:1 692.7 C18:1, C16:0, C6:0 Oleic acid, palmitic acid, caproic acid
TAG9 C42:2 718.7 C18:2, C12:0, C12:0 Linoleic acid, lauric acid, lauric acid
TAG10 C42:1 720.7 C12:0, C14:0, C16:1 Lauric acid, myristic acid, palmitoleic acid
TAG12 C44:3 744.7 C18:2, C16:1, C10:0 Linoleic acid, palmitoleic acid, capric acid
TAG13 C44:2 746.7 C18:2, C14:0, C12:0 Linoleic acid, myristic acid, lauric acid
TAG14 C44:1 748.7 C18:1, C16:0, C10:0 Oleic acid, palmitic acid, capric acid
TAG16A C46:4 770.7 C18:2, C18:2, C10:0 Linoleic acid, linoleic acid, capric acid
TAG17 C46:3 772.7 C18:2, C16:1, C12:0 Linoleic acid, palmitoleic acid, lauric acid
TAG18 C46:2 774.8 C18:2, C16:0, C12:0 Linoleic acid, palmitic acid, lauric acid
TAG19 C46:1 776.8 C18:1, C16:0, C12:0 Oleic acid, palmitic acid, lauric acid
TAG20 C46:0 778.8 C16:0, C16:0, C14:0 Palmitic acid, palmitic acid, myristic acid
TAG21 C48:5 796.7 C18:2, C18:3, C12:0 Linoleic acid, linolenic acid, lauric acid
TAG22 C48:4 798.7 C18:2, C18:2, C12:0 Linoleic acid, linoleic acid, lauric acid
TAG23 C48:3 800.8 C18:2, C16:1, C14:0 Linoleic acid, palmitoleic acid, myristic acid
TAG24 C48:2 802.8 C18:2, C16:0, C14:0 Linoleic acid, palmitic acid, myristic acid
TAG24A C48:2 802.8 C18:1, C16:1, C14:0 Oleic acid, palmitoleic acid, myristic acid
TAG25 C48:1 804.8 C18:1, C16:0, C14:0 Oleic acid, palmitic acid, myristic acid
TAG26 C48:0 806.7 C16:0, C16:0, C16:0 Palmitic acid, palmitic acid, palmitic acid
TAG27 C48: 818.7 C18:1, C16:0, C14: Oleic acid, palmitic acid, pentadecylic acid
TAG29 C50:6 822.7 C18:3, C18:3, C14:0 Linolenic acid, linolenic acid, myristic acid
TAG30 C50:5 824.7 C18:3, C16:1, C16:1 Linolenic acid, palmitoleic acid, palmitoleic acid
TAG31 C50:4 826.7 C18:2, C18:2, C14:0 Linoleic acid, linoleic acid, myristic acid
TAG32 C50:3 828.8 C16:1, C16:1, C18:1 Palmitoleic acid, palmitoleic acid, oleic acid
TAG33 C50:2 830.8 C18:2, C16:0, C16:0 Linoleic acid, palmitic acid, palmitic acid
TAG34 C50:1 832.8 C18:1, C16:0, C16:0 Oleic acid, palmitic acid, palmitic acid
TAG35 C50:0 834.7 C18:0, C16:0, C16:0 Stearic acid, palmitic acid, palmitic acid
TAG36 C51:3 842.6 C18:1, C16:1, C17:1 Oleic acid, palmitoleic acid, cis‑10‑heptadecenoic acid
TAG37 C50: 844.7 C18:1, C18:1, C14: Oleic acid, oleic acid, pentadecylic acid
TAG38 C51:1 846.7 C18:1, C17:0, C16:0 Oleic acid, heptadecanoic acid, palmitic acid
TAG39 C52:7 848.7 C18:3, C18:3, C16:1 Linolenic acid, linolenic acid, palmitoleic acid
TAG39A C51:0 848.7 C18:0, C17:0, C16:0 Stearic acid, heptadecanoic acid, palmitic acid
TAG40 C52:6 850.7 C18:2, C14:0, C20:4 Linoleic acid, myristic acid, C20:4
TAG40A C52:6 850.7 C18:3, C16:0, C18:3 Linolenic acid, palmitic acid, linolenic acid
TAG41 C52:5 852.7 C18:2, C18:2, C16:1 Linoleic acid, linoleic acid, palmitoleic acid
TAG42 C52:4 854.8 C18:2, C18:2, C16:0 Linoleic acid, linoleic acid, palmitic acid
TAG43 C52:3 856.8 C18:1, C18:1, C16:1 Oleic acid, oleic acid, palmitoleic acid
TAG44 C52:2 858.8 C18:1, C18:1, C16:0 Oleic acid, oleic acid, palmitic acid
TAG45 C52:1 860.8 C16:0, C18:1, C18:0 Palmitic acid, oleic acid, stearic acid
TAG46 C52:0 862.7 C18:0, C18:0, C16:0 Stearic acid, stearic acid, palmitic acid
TAG47 C53:5 866.7 C17:0, C17:1, C19:4 Heptadecanoic acid, cis‑10‑heptadecanoic acid, C19:4
TAG49A C53:1 870.7 C18:1, C18:2, C17:0 Oleic acid, linoleic acid, heptadecanoic acid
TAG52 C54:7 876.7 C18:2, C18:2, C18:3 Linoleic acid, linoleic acid, linolenic acid
TAG52A C54:7 876.7 C18:2, C18:2, C18:3 Linoleic acid, linoleic acid, linolenic acid
TAG53 C54:6 878.7 C18:2, C18:1, C18:3 Linoleic acid, oleic acid, linolenic acid
TAG53A C54:6 878.7 C18:2, C18:2, C18:2 Linoleic acid, linoleic acid, linoleic acid
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